重症COVID-19蛋白质组学特征验证
该前瞻性观察性队列研究纳入美国两家医院167例住院成人COVID-19患者,使用高通量平台检测713种血浆蛋白,按是否需要高流量鼻导管、机械通气、ECMO或死亡分为非重症与重症,在基线和之后每7天分类。基线有194种蛋白与重症相关,通路分析涉及炎症反应和组织修复。弹性网络逻辑回归得出14蛋白特征,在外部COVID-19数据集中区分90天死亡率AUC为0.92(95%CI 0.88-0.95)。根据该特征预测风险分类,患者对糖皮质激素治疗的反应存在异质性(p=0.006)。作者提出该14蛋白特征可能有助于开发COVID-19肺炎的精准医学方法。
要点
- 在167例住院COVID-19患者中检测713种血浆蛋白,基线194种蛋白与重症相关(重症定义为需要高流量鼻导管、机械通气、ECMO或死亡)。
- 采用弹性网络逻辑回归得到14蛋白特征,在外部COVID-19数据集中区分90天死亡率AUC为0.92(95%CI 0.88-0.95)。
- 根据该14蛋白特征预测风险分类,患者对糖皮质激素治疗的反应存在异质性(p=0.006)。
- 该研究为前瞻性观察性队列研究,美国两家医院,167例住院成人COVID-19患者,无干预。
适用人群与场景
- 美国两家医院住院的成人COVID-19患者167例。
- 研究在入院时及之后每7天将患者分类为非重症与重症COVID-19。
诊断标准与关键阈值
- 重症COVID-19定义为需要高流量鼻导管、机械通气、体外膜肺氧合(ECMO)或死亡。
- 非重症COVID-19为不符合上述重症定义者。
研究设计与关键结果
- 研究类型:前瞻性观察性队列研究,美国两家医院,167例住院成人COVID-19患者,无干预。
- 使用高通量平台检测713种血浆蛋白,在基线和之后每7天分类非重症与重症。
- 通过逻辑回归调整年龄、性别、症状持续时间和合并症,比较两组基线蛋白。
- 194种蛋白在入院时与重症COVID-19相关。
- 通路分析识别出多个与炎症反应和组织修复程序相关的通路。
- 以失调通路的先导蛋白为输入,弹性网络逻辑回归得出14蛋白特征。
- 该14蛋白特征在外部COVID-19数据集中区分90天死亡率AUC为0.92(95%CI 0.88-0.95)。
- 根据该特征预测风险对患者分类,发现对糖皮质激素治疗的反应存在异质性(p=0.006)。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究(含外部验证数据集)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者提出14蛋白特征可能有助于开发COVID-19肺炎的精准医学方法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: COVID-19 is a heterogenous disease. Biomarker-based approaches may identify patients at risk for severe disease, who may be more likely to benefit from specific therapies. Our objective was to identify and validate a plasma protein signature for severe COVID-19.
DESIGN: Prospective observational cohort study.
SETTING: Two hospitals in the United States.
PATIENTS: One hundred sixty-seven hospitalized adults with COVID-19.
MEASUREMENTS AND MAIN RESULTS: We measured 713 plasma proteins in 167 hospitalized patients with COVID-19 using a high-throughput platform. We classified patients as nonsevere versus severe COVID-19, defined as the need for high-flow nasal cannula, mechanical ventilation, extracorporeal membrane oxygenation, or death, at study entry and in 7-day intervals thereafter. We compared proteins measured at baseline between these two groups by logistic regression adjusting for age, sex, symptom duration, and comorbidities. We used lead proteins from dysregulated pathways as inputs for elastic net logistic regression to identify a parsimonious signature of severe disease and validated this signature in an external COVID-19 dataset. We tested whether the association between corticosteroid use and mortality varied by protein signature. One hundred ninety-four proteins were associated with severe COVID-19 at the time of hospital admission. Pathway analysis identified multiple pathways associated with inflammatory response and tissue repair programs. Elastic net logistic regression yielded a 14-protein signature that discriminated 90-day mortality in an external cohort with an area under the receiver-operator characteristic curve of 0.92 (95% CI, 0.88-0.95). Classifying patients based on the predicted risk from the signature identified a heterogeneous response to treatment with corticosteroids (p = 0.006).
CONCLUSIONS: Inpatients with COVID-19 express heterogeneous patterns of plasma proteins. We propose a 14-protein signature of disease severity that may have value in developing precision medicine approaches for COVID-19 pneumonia.
参考来源
- Cosgriff CV, Miano TA, Mathew D, et al. Validating a Proteomic Signature of Severe COVID-19. Crit Care Explor. 2022. PMID: 36479446. doi:10.1097/CCE.0000000000000800
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。